Latest Close
$2.08
Stock Hub
ADIL
Adial Pharmaceuticals, Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$15.17 (-87.94%)
Market Cap
$4,458,731.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$1.31 to $19.00
Target Mean Price
$25.00
Beta
1.27
Trailing P/E
Not available
Forward P/E
-0.84
Price / Book
0.44
Company Overview
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.